Your AI-Trained Oncology Knowledge Connection!

Video

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

Author(s):

Hans Hammers, MD, PhD,Moshe Ornstein, MD

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Bradley McGregor, MD
Regina Barragan-Carrillo, MD
Kathryn E. Beckermann, MD, PhD
Hedyeh Ebrahimi, MD, MPH
Axel Merseburger, MD, PhD
Laurence Albigès, MD, PhD
Charles B. Nguyen, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Yousef Zakharia, MD
Nazli Dizman, MD
Related Content
Image Credit: Sebastian Kaulitzki – stock.adobe.com
March 21st 2025

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com
March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

Cemiplimab Plus Chemotherapy in Advanced/Metastatic Penile Carcinoma | Image Credit: © Katsyarina – stock.adobe.com
March 11th 2025

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma